FORM 4

obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person*

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

NABI BIOPHARMACEUTICALS [NABI]

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

2. Issuer Name and Ticker or Trading Symbol

OMB APP	ROVAL
OMB Number:	3235-028

5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

Check this box if no longer subject to Section 16. Form 4 or Form 5 Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OIVID AFFROVAL								
OMB Number: 3235-028								
Estimated average burden								
hours per response:	0.5							

<u>JENCE</u>	$\frac{N_{I}}{N_{I}}$	<u>ABI</u>	BIC	<u>)PHA</u>	RN	<u>//ACI</u>	<u> </u>	<u> </u>	<u>S</u> [:	NAB		X [i appiii Directo			10% O	wner				
(Last) (First) (Middle) C/O NABI BIOPHARMACEUTICALS							3. Date of Earliest Transaction (Month/Day/Year) 05/13/2004											(give title		Other (below)	specify
5800 PA	RK OF CO	4. I	4. If Amendment, Date of Original Filed (Month/Day/Year)											6. Individual or Joint/Group Filing (Check Applicable Line)							
(Street) BOCA F	RATON F	Ĺ	33487											Lin	X Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City)	(S	tate)	(Zip)																		
		Tab	le I - Noi	n-Deriv	ative	e Se	curiti	ies Ac	qui	ired, [Dis	osed o	of, o	r Ber	neficia	ly O	wned	l .			
1. Title of Security (Instr. 3) 2. Trai Date (Monti					action Day/Ye	ar) l	2A. Deemed Execution Date, if any (Month/Day/Year)		Code (Instr.		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 5)			d (A) or r. 3, 4 and	4 and Securit		es ally Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	٧	Amount			(A) or (D) P		Price	Transac (Instr. 3		tion(s)			(
Common Stock 05/					/2004					М		7,500	0 A		\$2.81	13	14,247		D		
		ī	able II -									sed of onverti				/ Ow	ned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Da	Date,	4. Transa Code (8)		of Deri Secu Acq (A) o Disp of (E	oosed D) tr. 3, 4	Exp	Date Exe Diration I Onth/Day	Date		7. Title and Amount of Securities Underlying Derivative Secu (Instr. 3 and 4)		Security	Deriv Secu	3. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	e s Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exe	e ercisable		xpiration ate	Title		Amount or Number of Shares						
Stock Option (right to	\$2.813	05/13/2004			M			7,500	11/2	/28/1999	0	5/28/2004		nmon	7,500	\$	60	0		D	

Explanation of Responses:

Remarks:

buy)

/s/ James E. Dawson, as attorney-in-fact

05/17/2004

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.